Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 18/20 | 0.73 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
| ▸ | CDKL4 | Q5MAI5 | 1/20 | 0.39 |
| ▸ | CDKL3 | Q8IVW4 | 1/20 | 0.39 |
| ▸ | TAF1L | Q8IZX4 | 1/20 | 0.39 |
| ▸ | CDKL2 | Q92772 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23548872 | 0.88 | EIF2AK4 (0.78) | EIF2AK4CCND3MAPK10CDK6CDKL4 | |
| SCHEMBL23548675 | 0.88 | EIF2AK4 (0.75) | EIF2AK4MAPK6CCND3MAPK10CDK6 | |
| SCHEMBL23548356 | 0.86 | EIF2AK4 (0.78) | EIF2AK4CCND3MAPK10CDK6CDKL4 | |
| SCHEMBL23548325 | 0.86 | EIF2AK4 (0.85) | EIF2AK4 | |
| SCHEMBL23548682 | 0.85 | EIF2AK4 (0.76) | EIF2AK4CCND3MAPK10CDK6CDKL4 | |
| SCHEMBL23548381 | 0.85 | EIF2AK4 (0.73) | EIF2AK4PDE4B | |
| SCHEMBL23548661 | 0.84 | EIF2AK4 (1.00) | EIF2AK4PDE4B | |
| SCHEMBL23548942 | 0.84 | EIF2AK4 (1.00) | EIF2AK4PDE4B | |
| SCHEMBL23548279 | 0.84 | EIF2AK4 (0.82) | EIF2AK4 | |
| SCHEMBL23548736 | 0.84 | EIF2AK4 (0.74) | EIF2AK4CCND3MAPK10CDK6CDKL4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | RAPT THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | RAPT THERAPEUTICS, INC. (US) | 2021-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046699-B2 | Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses | GLS, GLS2, TK2 | EIF2AK4 1089/4885MAPK6 2736/4885PDE4B 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.